Stocks in play: Medexus Pharmaceuticals

Announced preliminary estimates of the company’s revenue results for the fiscal quarter ended September 30, 2022 (the company’s fiscal Q2 2023). All dollar amounts are in U.S. dollars unless specified otherwise. Medexus expects to deliver total revenue between $27.0 million and $27.5 million in fiscal Q2 2023. This will represent the strongest fiscal quarter in Medexus’s history, and an increase of at least 51% compared to $17.9 million in fiscal Q2 2022 and an increase of at least 17% compared to $23.0 million in fiscal Q1 2023. Primary drivers for the most recent quarter’s revenue performance were organic increases in net sales across Medexus’s portfolio, which now includes recognition of 100% of revenue from Gleolan sales in the United States starting September 2022. Medexus Pharmaceuticals shares T.MDP are trading up $0.23 at $1.29.

Read: